Back to Search Start Over

Vaccine for Diabetes—Where Do We Stand?

Authors :
Chellappan, Dinesh Kumar
Bhandare, Richie R.
Shaik, Afzal B.
Prasad, Krishna
Suhaimi, Nurfatihah Azlyna Ahmad
Yap, Wei Sheng
Das, Arpita
Banerjee, Pradipta
Ghosh, Nandini
Guith, Tanner
Das, Amitava
Balakrishnan, Sarannya
Candasamy, Mayuren
Mayuren, Jayashree
Palaniveloo, Kishneth
Gupta, Gaurav
Singh, Sachin Kumar
Dua, Kamal
Source :
International Journal of Molecular Sciences; Aug2022, Vol. 23 Issue 16, p9470-N.PAG, 16p
Publication Year :
2022

Abstract

Diabetes is an endocrinological disorder with a rapidly increasing number of patients globally. Over the last few years, the alarming status of diabetes has become a pivotal factor pertaining to morbidity and mortality among the youth as well as middle-aged people. Current developments in our understanding related to autoimmune responses leading to diabetes have developed a cause for concern in the prospective usage of immunomodulatory agents to prevent diabetes. The mechanism of action of vaccines varies greatly, such as removing autoreactive T cells and inhibiting the interactions between immune cells. Currently, most developed diabetes vaccines have been tested in animal models, while only a few human trials have been completed with positive outcomes. In this review, we investigate the undergoing clinical trial studies for the development of a prototype diabetes vaccine. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
16616596
Volume :
23
Issue :
16
Database :
Complementary Index
Journal :
International Journal of Molecular Sciences
Publication Type :
Academic Journal
Accession number :
158847666
Full Text :
https://doi.org/10.3390/ijms23169470